top of page

Nature serves as a rich source of inspiration. We've ingeniously harnessed enzymes and nucleic acids, transforming them into powerful tools like genome editors and PCR diagnostics. Nevertheless, nature's abundant offerings have sometimes confined us within the 'resource curse' paradigm, wherein biology has predominantly involved tweaking existing molecules. To unlock the full potential of biotechnology, enabling solutions to pressing challenges like aging, climate change, and sustainable energy, we must liberate ourselves from this cycle. The key lies in embracing Generative AI (GAI) and Quantum Mechanics AI (QMAI).

Compute Beyond Nature

At Quantum Sky, we develop Generative and Quantum AI models and apply them to expand Biology's Horizons

Quantum Leaped Technologies
the Sky's the Limit

Our AI engine, the SkyEngine, comprises LLM and QMAI models. Its architecture allows unified implementation on both proteins and RNAs. Conceived in 2020, it has been iterated over the past few year to become the state-of-the-art for biomachine generation and optimization.



Jorna Therapeutics works on RNA editing. With SkyEngine de novo-designed RNA search engine, CasNova, its NanoBE and NanoPE systems are revolutionizing what's possible with RNA manipulation.

RNA Editing

Kana works on genome editing, and it is currently in stealth mode.

Kana Medicine

Genome Writing

Entrega aims to build the next generation delivery systems for nucleic acid medicines. Its VAILs (vehicles by AI layering) are a new class of delivery tools created by our generative AI.


750 Main Street

Cambridge, MA 02139, USA

We are working on the first phase of Quantum Sky, and would love to hear from you! If you are interested in our updates, please hit the "Subscribe" button below. If you want to reach out and chat, please send us a note through the contact form. We look forward to hearing from you.


Thanks for contacting us!

Enter, SkyEngine

SkyEngine, our AI engine that integrates both GAI and QMAI, operates on both proteins and RNAs with expanded alphabet. The biomachines it generates have translated into tangible products, making a real-world impact. For instance, it has facilitated the creation of de novo-designed CRISPR-Cas proteins, aiding our clients in launching COVID-19 diagnostic kits and RNA editing pipelines.

Due to its unique architecture, SkyEngine outputs models that are interactive and can answer key questions such as ligand binding and working pH. Instead of offering a static structure, our model offers a dynamic view of the biomachines it builds.


Compared with Nature's selection of 20 amino acids, SkyEngine expands the alphabet to more than 400 amino acids and other non-canonical bases for building proteins and RNAs


Compared with the state-of-the-art models, our models achieves more than 10 million times acceleration using QMAI and 


It only takes a few examples for the SkyEngine to generate working de novo proteins


bottom of page